Featured 13F manager
DME Capital Management David Einhorn
New York, NY 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $3.9B
- 46 holds
- 2026 Q2
- +22.5% QoQ
- Top 5 38.2%
David Einhorn files DME Capital Management as a Form 13F. The latest book is 2026 Q2 at $3.9B, up 22.5% QoQ, led by Green Brick Partners, Fluor, and Core Natural Resources.
Portfolio
top 5 38.2% · top 10 52.8%
- GRBK - Green Brick Partners 19.4%
- FLR - Fluor 6.2%
- CNR - Core Natural Resources 4.7%
- BHF - Brighthouse Finl 4.6%
- ACHC — 3.3%
- PENN - Penn Entertainment 3.2%
- FBIN - Fortune Brands 3.1%
- PCG - Pg And E 2.9%
- CNC - Centene Del 2.7%
- PKG - Graphic Packaging 2.7%
- SNX - Td Synnex 2.6%
- TEVA - Teva Pharmaceutical Inds 2.5%
- Other 42.1%
AUM over time
Book
| GRBK - Green Brick Partners | Hold | 10,467,383 | $57.24 | $599M | — | — | |
| CEIXEUR - Consol Energy | Hold | 1,640,750 | $102.03 | $167M | — | — | |
| BHF - Brighthouse Finl | Reduce −1.6% | 2,973,031 | $43.34 | $129M | −48,732 | −$27M | |
| HPQ - HP | Add +108.7% | 3,373,030 | $35.02 | $118M | +1,757,070 | +$69M | |
| KD - Kyndryl | Reduce −32.8% | 4,435,819 | $26.31 | $117M | −2,169,240 | −$27M | |
| PENN - Penn Entertainment | Add +11.9% | 5,095,340 | $19.36 | $99M | +540,630 | +$16M | |
| ODP1 - The Odp | Add +29.9% | 2,222,470 | $39.27 | $87M | +511,890 | −$3M | |
| ALITEUR - Alight · CL A | Reduce −3.9% | 11,074,090 | $7.38 | $82M | −453,840 | −$32M | |
| THC - Tenet Healthcare | Reduce −32.9% | 597,677 | $133.03 | $80M | −292,953 | −$14M | |
| VTRS - Viatris | Add +63.8% | 7,399,810 | $10.63 | $79M | +2,882,190 | +$25M | |
| TECK - Teck Resources · CL B | Reduce −30.0% | 1,086,663 | $47.90 | $52M | −465,400 | −$19M | |
| ROIV - Roivant Sciences | Add +14.8% | 4,810,960 | $10.57 | $51M | +620,470 | +$7M | |
| DHT — | Hold | 4,024,340 | $11.57 | $47M | — | — | |
| GLD - Spdr Gold Tr | Reduce −18.0% | 202,331 | $215.01 | $44M | −44,340 | −$7M | |
| PKG - Graphic Packaging | Reduce −22.3% | 1,396,130 | $26.21 | $37M | −400,000 | −$16M | |
| LBTYA - Liberty Global · CL A | Hold | 2,041,580 | $17.43 | $36M | — | — | |
| LIVN - Livanova | Reduce −51.7% | 644,269 | $54.82 | $35M | −688,535 | −$39M | |
| SDRL - Seadrill 2021 | Hold | 569,405 | $51.50 | $29M | — | — | |
| PTON - Peloton Interactive · CL A | New | 6,789,140 | $3.38 | $23M | +6,789,140 | +$23M | |
| CPRI - Capri | New | 684,770 | $33.08 | $23M | +684,770 | +$23M | |
| WFRD - Weatherford Intl | Reduce −44.1% | 177,339 | $122.45 | $22M | −140,138 | −$15M | |
| RSP — | Hold | 182,511 | $102.72 | $19M | — | — | |
| XAR - Spdr Ser Tr | Hold | 127,557 | $139.98 | $18M | — | — | |
| IAC - IAC Inc | New | 291,460 | $46.85 | $14M | +291,460 | +$14M | |
| COYA - Coya Therapeutics | Hold | 1,274,026 | $6.06 | $8M | — | — | |
| LKFT - Galapagos | Add +46.9% | 234,828 | $24.78 | $6M | +75,000 | +$673K | |
| TEVA - Teva Pharmaceutical Inds | Hold | 324,850 | $16.25 | $5M | — | — | |
| GPRO - Gopro · CL A | Hold | 2,823,100 | $1.42 | $4M | — | — | |
| GDX - Vaneck ETF Trust | Hold | 111,390 | $33.93 | $4M | — | — | |
| SHC - Sotera Health | Hold | 300,110 | $11.87 | $4M | — | — | |
| OIH - Vaneck ETF Trust | Hold | 11,220 | $316.18 | $4M | — | — | |
| FCG - First Tr Exchange-Traded Fd | Hold | 70,830 | $26.28 | $2M | — | — | |
| Danimer Scientific · CL A | Hold | 2,734,580 | $0.6032 | $2M | — | — | |
| IVZ - Invesco Actvely Mngd Etc Fd | Hold | 117,360 | $14.05 | $2M | — | — | |
| TLIS - Talis Biomedical | Hold | 149,052 | $8.66 | $1M | — | — | |
| GANX - Gain Therapeutics | Hold | 566,130 | $1.28 | $725K | — | — | |
| NUVB - Nuvation Bio · CL A | Hold | 34,995 | $2.92 | $102K | — | — |
Exits / last held
Not current holdings · last reported size, unchanged · gone vs 2024 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| FCNCA - First Ctzns Bancshares · CL A | Exit | 0 | $1,635 | $41M | −25,160 | −$41M | |
| AER - Aercap | Exit | 0 | $86.91 | $28M | −319,050 | −$28M | |
| NPWR - Net Power · CL A | Exit | 0 | $11.39 | $22M | −1,959,280 | −$22M | |
| KVUE - Kenvue | Exit | 0 | $21.46 | $15M | −707,740 | −$15M | |
| CLVT - Clarivate | Exit | 0 | $7.43 | $2M | −279,560 | −$2M | |
| OHRPEUR - Neubase Therapeutics | Exit | 0 | $0.4474 | $61K | −136,350 | −$61K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holds | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 46 | $3.9B | +22.5% | 13F-HR | 8/14/2026 | 000117266126003786 |
| 2026 Q1 | 45 | $3.2B | +12.0% | 13F-HR | 5/15/2026 | 000117266126002341 |
| 2025 Q4 | 41 | $2.8B | +12.1% | 13F-HR | 2/17/2026 | 000117266126001122 |
| 2025 Q3 | 37 | $2.5B | +9.3% | 13F-HR | 11/14/2025 | 000117266125005032 |
| 2025 Q2 | 34 | $2.3B | +17.8% | 13F-HR | 8/14/2025 | 000117266125003351 |
| 2025 Q1 | 33 | $2B | +1.5% | 13F-HR | 5/15/2025 | 000117266125002307 |
| 2024 Q4 | 36 | $1.9B | −19.1% | 13F-HR | 2/14/2025 | 000117266125001165 |
| 2024 Q3 | 38 | $2.4B | +17.6% | 13F-HR | 11/14/2024 | 000117266124005240 |
| 2024 Q2 | 39 | $2B | −6.5% | 13F-HR | 8/14/2024 | 000117266124003549 |
| 2024 Q1 | 42 | $2.2B | — | 13F-HR | 5/15/2024 | 000117266124002489 |
| 2023 Q4 | 40 | $2B | +16.3% | 13F-HR | 2/14/2024 | 000117266124001512 |
| 2023 Q3 | 39 | $1.8B | −17.4% | 13F-HR | 11/14/2023 | 000117266123004012 |
| 2023 Q2 | 41 | $2.1B | +15.9% | 13F-HR | 8/14/2023 | 000117266123003174 |
| 2023 Q1 | 39 | $1.8B | +27.4% | 13F-HR | 5/15/2023 | 000117266123002282 |
| 2022 Q4 | 42 | $1.4B | +2.3% | 13F-HR | 2/14/2023 | 000117266123001336 |
| 2022 Q3 | 42 | $1.4B | +9.8% | 13F-HR | 11/14/2022 | 000117266122002565 |
| 2022 Q2 | 47 | $1.3B | −18.3% | 13F-HR | 8/15/2022 | 000117266122002019 |
| 2022 Q1 | 52 | $1.6B | −10.0% | 13F-HR | 5/16/2022 | 000117266122001474 |
| 2021 Q4 | 57 | $1.7B | +17.2% | 13F-HR | 2/14/2022 | 000117266122000884 |
| 2021 Q3 | 58 | $1.5B | — | 13F-HR | 11/15/2021 | 000117266121002370 |
About
DME Capital Management
20 processed 13Fs on this site · 2021 Q3–2026 Q2